Evidence map›Paper›PMID 35966764›Full record

ArticleHemaSphere2022

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany.

Krischan Braitsch, Laura K Schmalbrock, Paul Jung, Irmgard Bumeder, Philipp Kiewe, Judith S Hecker, Mareike Verbeek, Jörg Westermann, Lars Bullinger, Ulrich Keller and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Krischan BraitschDepartment of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
Laura K SchmalbrockDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Paul JungDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Irmgard BumederPraxis und Tagesklinik für Hämatologie und internistische Onkologie, Munich, Germany.
Philipp KieweOnkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany.
Judith S HeckerDepartment of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
Mareike VerbeekDepartment of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
Jörg WestermannDepartment of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Lars BullingerBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany.
Ulrich KellerDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Florian BassermannDepartment of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
Jan KrönkeDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Katharina S GötzeDepartment of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
Kathrin RiegerDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35966764
PMCPMC9365332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.